These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 18004453)

  • 41. Towards the clinic: intelligent design of nanomedicines for cancer treatment.
    Andón FT; Pazinatto DB; Fadeel B
    Nanomedicine (Lond); 2012 Sep; 7(9):1293. PubMed ID: 22994956
    [No Abstract]   [Full Text] [Related]  

  • 42. Spectroscopic probes of molecular recognition.
    Suhm MA
    Phys Chem Chem Phys; 2007 Aug; 9(32):4443. PubMed ID: 17690768
    [No Abstract]   [Full Text] [Related]  

  • 43. Fluorocoxib A loaded nanoparticles enable targeted visualization of cyclooxygenase-2 in inflammation and cancer.
    Uddin MJ; Werfel TA; Crews BC; Gupta MK; Kavanaugh TE; Kingsley PJ; Boyd K; Marnett LJ; Duvall CL
    Biomaterials; 2016 Jun; 92():71-80. PubMed ID: 27043768
    [TBL] [Abstract][Full Text] [Related]  

  • 44. RGD-conjugated two-photon absorbing near-IR emitting fluorescent probes for tumor vasculature imaging.
    Yue X; Morales AR; Githaiga GW; Woodward AW; Tang S; Sawada J; Komatsu M; Liu X; Belfield KD
    Org Biomol Chem; 2015 Nov; 13(43):10716-25. PubMed ID: 26351137
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HS-133, a novel fluorescent phosphatidylinositol 3-kinase inhibitor as a potential imaging and anticancer agent for targeted therapy.
    Lee JH; Jung KH; Lee H; Son MK; Yun SM; Ahn SH; Lee KR; Lee S; Kim D; Hong S; Hong SS
    Oncotarget; 2014 Oct; 5(20):10180-97. PubMed ID: 25338206
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optical imaging of tumor microenvironment.
    Wu Y; Zhang W; Li J; Zhang Y
    Am J Nucl Med Mol Imaging; 2013; 3(1):1-15. PubMed ID: 23342297
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Radiolytic reduction characteristics of artificial oligodeoxynucleotides possessing 2-oxoalkyl group or disulfide bonds.
    Tanabe K; Ito T; Nishimoto S
    J Nucleic Acids; 2011; 2011():816207. PubMed ID: 21860782
    [TBL] [Abstract][Full Text] [Related]  

  • 48. White light-mediated Cu (II)-5FU interaction augments the chemotherapeutic potential of 5-FU: an in vitro study.
    Chibber S; Farhan M; Hassan I; Naseem I
    Tumour Biol; 2011 Oct; 32(5):881-92. PubMed ID: 21618035
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals.
    Kobayashi H; Longmire MR; Ogawa M; Choyke PL
    Chem Soc Rev; 2011 Sep; 40(9):4626-48. PubMed ID: 21607237
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1.
    Nishida CR; Lee M; de Montellano PR
    Mol Pharmacol; 2010 Sep; 78(3):497-502. PubMed ID: 20566689
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents.
    Uddin MJ; Crews BC; Blobaum AL; Kingsley PJ; Gorden DL; McIntyre JO; Matrisian LM; Subbaramaiah K; Dannenberg AJ; Piston DW; Marnett LJ
    Cancer Res; 2010 May; 70(9):3618-27. PubMed ID: 20430759
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mechanism-based profiling of MMPs.
    Fisher JF; Mobashery S
    Methods Mol Biol; 2010; 622():471-87. PubMed ID: 20135299
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Radiation- and photo-induced activation of 5-fluorouracil prodrugs as a strategy for the selective treatment of solid tumors.
    Ito T; Tanabe K; Yamada H; Hatta H; Nishimoto S
    Molecules; 2008 Oct; 13(10):2370-84. PubMed ID: 18830160
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design of anticancer prodrugs for reductive activation.
    Chen Y; Hu L
    Med Res Rev; 2009 Jan; 29(1):29-64. PubMed ID: 18688784
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New radiosensitizing regimens, drugs, prodrugs, and candidates.
    Vallerga AK; Zarling DA; Kinsella TJ
    Clin Adv Hematol Oncol; 2004 Dec; 2(12):793-805. PubMed ID: 16166960
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phage peptide display.
    Newton J; Deutscher SL
    Handb Exp Pharmacol; 2008; (185 Pt 2):145-63. PubMed ID: 18626602
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current molecular design of intelligent drugs and imaging probes targeting tumor-specific microenvironments.
    Tanabe K; Zhang Z; Ito T; Hatta H; Nishimoto S
    Org Biomol Chem; 2007 Dec; 5(23):3745-57. PubMed ID: 18004453
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Molecular design of hypoxic tumor cell-targeting drugs and imaging probes].
    Tanabe K; Ito T; Nishimoto S
    Tanpakushitsu Kakusan Koso; 2007 Oct; 52(13 Suppl):1588-93. PubMed ID: 18051384
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.